Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
US Department of Justice
Daiichi Sankyo
Merck
Harvard Business School
Queensland Health
Mallinckrodt
Medtronic

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020983

« Back to Dashboard

NDA 020983 describes VENTOLIN HFA, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from thirteen suppliers. There are fifteen patents protecting this drug. Additional details are available on the VENTOLIN HFA profile page.

The generic ingredient in VENTOLIN HFA is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.
Summary for 020983
Tradename:VENTOLIN HFA
Applicant:Glaxosmithkline
Ingredient:albuterol sulfate
Patents:15
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020983
Mechanism of ActionAdrenergic beta2-Agonists
Suppliers and Packaging for NDA: 020983
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983 NDA GlaxoSmithKline LLC 0173-0682 N 0173-0682-20
VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983 NDA GlaxoSmithKline LLC 0173-0682 N 0173-0682-21

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrengthEQ 0.09MG BASE/INH
Approval Date:Apr 19, 2001TE:BXRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jul 16, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Jun 23, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Jun 23, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 020983

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983-001 Apr 19, 2001 ➤ Sign Up ➤ Sign Up
Glaxosmithkline VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983-001 Apr 19, 2001 ➤ Sign Up ➤ Sign Up
Glaxosmithkline VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983-001 Apr 19, 2001 ➤ Sign Up ➤ Sign Up
Glaxosmithkline VENTOLIN HFA albuterol sulfate AEROSOL, METERED;INHALATION 020983-001 Apr 19, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Boehringer Ingelheim
Express Scripts
Chinese Patent Office
Farmers Insurance
Cipla
QuintilesIMS
Fuji
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.